-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QYiJyNClhFwTQqlzWuFCZA8ofOl8Cr3eZIethcvI2xgPArZRZIsAdyR+Tz1yeKsN
 5puTdqOao8s5Kbob1Ln1Ig==

<SEC-DOCUMENT>0000012208-09-000017.txt : 20090505
<SEC-HEADER>0000012208-09-000017.hdr.sgml : 20090505
<ACCEPTANCE-DATETIME>20090505164038
ACCESSION NUMBER:		0000012208-09-000017
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090505
DATE AS OF CHANGE:		20090505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		09798158

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8kcover03312009.htm
<DESCRIPTION>FORM 8-K - PRESS RELEASE
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="04/21/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: May 5, 2009</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Commission File Number: 1-7928</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=562.733><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=565.6><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=616.267><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=615><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=285.933></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=285.933><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">On May 5, 2009, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the quarter ended March 31, 2009. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated May 5, 2009</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">May 5, 2009</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="margin:0px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Christine A. Tsingos </P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Exhibit</B></P>
<P style="line-height:12px; margin:0px; font-size:9.333px"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:9.333px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated May 5, 2009</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99103312009.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="11/06/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:18.667px; margin:0px; font-size:16px" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=631.2></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:14.667px"><FONT FACE="Arial">FOR IMMEDIATE RELEASE</FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:17.333px; margin:0px; padding-right:-24px; font-family:Arial; font-size:14.667px" align=center><B>BIO-RAD REPORTS FIRST-QUARTER &nbsp;&nbsp;</B></P>
<P style="line-height:17.333px; margin:0px; padding-right:-24px; font-family:Arial; font-size:14.667px" align=center><B>2009 FINANCIAL RESULTS</B></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">HERCULES, CA &#150; May 5, 2009 &#150;<FONT COLOR=#0000FF> </FONT>Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March &nbsp;31, 2009.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">First-quarter<FONT COLOR=#0000FF> </FONT>reported revenues were<FONT COLOR=#0000FF> </FONT>$400.9 million, down 5.0%<FONT COLOR=#0000FF> </FONT>compared to $422.2 million reported for the first quarter of 2008<FONT COLOR=#0000FF>. </FONT>On a currency-neutral basis, quarterly revenues<FONT COLOR=#0000FF> </FONT>increased 3.2% compared to the same period last year.<FONT COLOR=#0000FF> </FONT>Net income attributable to Bio-Rad for the first quarter was<FONT COLOR=#0000FF> </FONT>$30.3 million, or $1.10 per share on a fully diluted basis, compared to $26.5 million or $0.96 per share, respectively, during the same period last year. Reflected in operating income are $5.4 million of amortization and purchase accounting adjustments for the first quarter of 2009 associated with the DiaMed acquisition, a decrease of approximately $1.0 million versus the first quarter of 2008.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">First-quarter gross margin was stronger than usual at 57.1%<FONT COLOR=#0000FF> </FONT>compared to 53.7% during the same quarter last year.<FONT COLOR=#0000FF> </FONT>The higher margin in the first quarter of 2009 was the result of favorable sales mix and improved manufacturing efficiencies, as well as some favorable, non-recurring events.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">&#147;Performance for the first quarter of 2009 shows continued progress in spite of a weakened global economy and currency headwinds,&#148;<FONT COLOR=#0000FF> </FONT>said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &#147;While there is still uncertainty about the economy, we are encouraged by the resilience of our markets to date.&#148; </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:14.667px" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><P style="line-height:21.333px; padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always" align=center><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=631.2></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:14.667px">Bio-Rad Reports First-Quarter 2009 Financial Results</P>
<P style="line-height:17.333px; margin:0px; font-family:Arial; font-size:14.667px">Page 2</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Life Science </P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">The Life Science segment net sales for the quarter were $140.3 million, down 9.2% or 3.0% on a currency-neutral basis, compared to the same period last year. Performance of the Life Science segment was negatively impacted by a general slowness in the research market in the U.S. and Europe. In addition, the timing of the delivery of certain process chromatography products in the first quarter last year had an adverse impact on the comparison to the first quarter this year. Sales across a number of product lines in the Life Science segment performed well during the quarter, in particular the Bio-Plex<SUP>&#174;</SUP> suspension array system assays and the Company&#146;s real-time polymerase chain reaction (PCR) instruments and reagents. &nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Clinical Diagnostics</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">The Clinical Diagnostics segment reported net sales of $257.5 million for the quarter, down 2.3% compared to the first quarter in 2008.<FONT COLOR=#0000FF> </FONT>On a currency-neutral basis, sales for the segment increased 7.2%. These results reflect continued growth across all product lines, most notably quality control, diabetes, microbiology, and blood virus testing products. Performance in this segment also benefited from placements of the Company&#146;s BioPlex<SUP>&#174; </SUP>2200 system, which employs multiplexing technology to analyze multiple disease markers from a single patient sample.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) May 5, 2009.<FONT COLOR=#0000FF> </FONT>Interested parties may access the call by dialing 800-561-2718 (in the U.S.) or 617-614-3525 (international), access number<FONT COLOR=#0000FF> </FONT>62277042.<FONT COLOR=#0000FF> </FONT>The live webcast may also be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 51476577 for seven days following the call, and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">About Bio-Rad</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:14.667px" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
</TD></TR>
</TABLE>
<P style="line-height:21.333px; margin:0px" align=center><P style="line-height:21.333px; padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=631.2></TD></TR>
<TR><TD valign=top width=631.2><P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-family:Arial; font-size:14.667px">Bio-Rad Reports First-Quarter 2009 Financial Results</P>
<P style="line-height:17.333px; margin:0px; font-family:Arial; font-size:14.667px">Page 3</P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, please visit www.bio-rad.com. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-family:Arial; font-size:14.667px">This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s most recent Annual Report on
 Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">For more information contact:</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px">investor_relations@bio-rad.com</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:Arial; font-size:14.667px" align=center>(more)</P>
</TD></TR>
</TABLE>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=392.8></TD><TD width=12></TD><TD width=96></TD><TD width=12></TD><TD width=96></TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center><FONT FACE="Times New Roman">BIO-RAD LABORATORIES, INC.</FONT></P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="margin:0px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=608.8 colspan=5><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=204 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=204 colspan=3><P style="margin:0px" align=center>Three Months Ended</P>
</TD></TR>
<TR><TD valign=top width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=204 colspan=3><P style="margin:0px" align=center>March 31,</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin:0px" align=center>2009</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin:0px" align=center>2008</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px">Net sales</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;400,933&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;422,197&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:28.8px">Cost of goods sold</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>172,031&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>195,314&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px">Gross profit</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>228,902&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>226,883&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Selling, general and administrative expense</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>140,313&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>139,655&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Product research and development expense</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>37,152&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>37,489&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Income from operations</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>51,437&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>49,739&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Interest expense</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>7,807&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="margin:0px" align=right>7,957&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Foreign exchange (gains) losses, net</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>(774)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>2,593&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Other (income) expense, net</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>1,159&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(193)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Income before taxes </P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>43,245&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>39,382&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Provision for income taxes</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(11,202)</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(10,823)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Net income</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>32,043&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="margin:0px" align=right>28,559&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Less: Net income attributable to noncontrolling interests</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(1,778)</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=96><P style="margin:0px" align=right>(2,064)</P>
</TD></TR>
<TR><TD width=392.8><P style="margin:0px">Net income attributable to Bio-Rad</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;30,265&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;&nbsp;&nbsp;26,495&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px">Basic earnings per share:</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Net income attributable to Bio-Rad</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;1.11&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;0.98&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Weighted average common shares</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>27,321&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>26,955&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px">Diluted earnings per share:</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="margin:0px; text-indent:48px">Net income attributable to Bio-Rad</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;1.10&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>$ &nbsp;0.96&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=392.8><P style="margin:0px; text-indent:48px">Weighted average common shares</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>27,618&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=96><P style="margin:0px" align=right>27,538&nbsp;</P>
</TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=392.8><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=608.8 colspan=5><P style="margin:0px">The accompanying notes are an integral part of these condensed consolidated financial statements.</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><BR></P>
<P style="margin:0px" align=center><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=391.667></TD><TD width=16.667></TD><TD width=104.467></TD><TD width=22.333></TD><TD width=108.533></TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px; font-size:12px" align=center>Condensed Consolidated Balance Sheets</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=643.667 colspan=5><P style="margin:0px; font-size:12px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=235.333 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=235.333 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=104.467><P style="margin:0px; font-size:12px" align=center>March 31,</P>
</TD><TD valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=108.533><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=104.467><P style="margin:0px; font-size:12px" align=center>2009</P>
</TD><TD valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=108.533><P style="margin:0px; font-size:12px" align=center>2008</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Current assets: </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Cash and cash equivalents</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;192,870&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;204,524&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Short-term investments</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>29,960&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>38,950&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="margin:0px; font-size:12px" align=right>326,307&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="margin:0px; font-size:12px" align=right>339,653&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Inventories, net </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>369,041&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>375,616&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>131,744&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>135,198&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current assets </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>1,049,922&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>1,093,941&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Net property, plant and equipment </P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>294,611&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>300,732&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; font-size:12px">Goodwill</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="margin:0px; font-size:12px" align=right>307,916&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="margin:0px; font-size:12px" align=right>321,820&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Purchased intangibles, net</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>211,245&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>228,590&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; font-size:12px">Other assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>91,614&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>92,181&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total assets</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,955,308&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Current liabilities:</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" valign=top width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=104.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6,253&nbsp;</P>
</TD><TD valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=108.533><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9,578&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts payable</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>95,952&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>117,982&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="margin:0px; font-size:12px" align=right>91,621&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="margin:0px; font-size:12px" align=right>119,420&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Sales, income and other taxes payable</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>36,739&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>33,731&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>125,314&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>137,323&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current liabilities</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>355,879&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>418,034&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Long-term debt, net of current maturities</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>444,209&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>445,979&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; font-size:12px">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>96,921&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>102,611&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; text-indent:19.2px; font-size:12px">Total liabilities</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=104.467><P style="margin:0px; font-size:12px" align=right>897,009&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=108.533><P style="margin:0px; font-size:12px" align=right>966,624&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; font-size:12px">Bio-Rad stockholders&#146;equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=104.467><P style="margin:0px; font-size:12px" align=right>1,026,612&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=108.533><P style="margin:0px; font-size:12px" align=right>1,040,731&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Noncontrolling interests</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>31,687&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>29,909&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="margin:0px; text-indent:38.4px; font-size:12px">Total stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=104.467><P style="margin:0px; font-size:12px" align=right>1,058,299&nbsp;</P>
</TD><TD width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=108.533><P style="margin:0px; font-size:12px" align=right>1,070,640&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" valign=top width=391.667><P style="margin:0px; font-size:12px">Total liabilities and stockholders&#146; equity</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" valign=top width=104.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,955,308&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" valign=top width=108.533><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2,037,264&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=104.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=22.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=108.533><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin-top:0px; margin-bottom:6px"><BR></P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=426.333></TD><TD width=77.333></TD><TD width=16.667></TD><TD width=77.333></TD></TR>
<TR><TD valign=top width=597.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=597.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=597.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=597.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=171.333 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=171.333 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Three Months Ended</P>
</TD></TR>
<TR><TD valign=top width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=171.333 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>March 31,</P>
</TD></TR>
<TR><TD valign=top width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=77.333><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2009</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=77.333><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2008</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from operating activities:</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash received from customers</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;395,356&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;436,521&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash paid to suppliers and employees</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(375,628)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(421,973)</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Interest paid</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(8,775)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(8,938)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Income tax payments</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(6,012)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(6,398)</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other operating activities</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>1,430&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,389)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by (used in) operating activities</P>
</TD><TD style="background-color:#CCFFCC; border-top:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>6,371&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-top:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(2,177)</P>
</TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from investing activities:</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Payments for acquisitions and long-term investments</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(441)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,106)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other investing activities</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(12,275)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(17,858)</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash used in investing activities</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(12,716)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(34,964)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from financing activities:</P>
</TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Payments on long-term debt</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(1,882)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(2,190)</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other financing activities</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(161)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>4,979&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Net cash provided by (used in) financing activities</P>
</TD><TD style="background-color:#CCFFCC; border-top:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(2,043)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-top:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>2,789&nbsp;</P>
</TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Effect of exchange rate changes on cash</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(3,266)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>2,068&nbsp;</P>
</TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net decrease in cash and cash equivalents</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(11,654)</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(32,284)</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at beginning of the period</P>
</TD><TD style="border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>204,524&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>161,764&nbsp;</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at end of period</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;192,870&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:2.667px double #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;129,480&nbsp;</P>
</TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=503.667 colspan=2><P style="line-height:14.667px; margin:0px; font-size:12px">Reconciliation of net income attributable to Bio-Rad to net cash provided by </P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=503.667 colspan=2><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">(used in) operating activities:</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net income attributable to Bio-Rad</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;30,265&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;26,495&nbsp;</P>
</TD></TR>
<TR><TD width=503.667 colspan=2><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Adjustments to reconcile net income attributable to Bio-Rad to net cash provided by </P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:6.733px; font-size:12px">(used in) operating activities:&nbsp;</P>
</TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Depreciation and amortization</P>
</TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>22,327&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>23,740&nbsp;</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Changes in working capital</P>
</TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(46,871)</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(60,027)</P>
</TD></TR>
<TR><TD style="background-color:#CCFFCC" width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other</P>
</TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>650&nbsp;</P>
</TD><TD style="background-color:#CCFFCC" width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="background-color:#CCFFCC; border-bottom:1px solid #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>7,615&nbsp;</P>
</TD></TR>
<TR><TD width=426.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net cash provided by (used in ) operating activities</P>
</TD><TD style="border-bottom:2.667px double #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;6,371&nbsp;</P>
</TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.333><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;(2,177)</P>
</TD></TR>
<TR><TD width=426.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.333><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
